NorthWest Biotherapeutics Inc (NWBO)

[georgebailey]

Eagle- Smith on Stocks in his report, under Artisan, is 100 per month and 1200 annually- this is based on his understanding that buildout phase 1a was 50/mo and 1B brings 100 month or 1200 annually- maintenance requirements goes down to 1000 annually.
Intro of Eden’s at 12x is 12,000 annually. This ties to Bosch comment at asco and ramping to 1000 monthly based on 1a and 1B using Eden’s.
I am not buying that 1000 annual patients/batches using Artisan/Smith translates to 144,000 annually with Eden’s.
From the Bosch prez, 20% of the facility is in use.
My Sawston capacity,fully built out, is 60k annual patients( 12,000x 5).
New annual GBM cases in the EU and UK is about 24k- the UK portion is near 3k.
Clearly Sawston can handle nGBM and rGBM and grade 3 Gliomas.
I hope I’m very wrong and your 144k is correct